During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Mats Jerkeman, Lund University, Lund, SE. We asked, Is a response-adapted treatment strategy feasible for patients with mantle cell lymphoma (MCL)?
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Is a response-adapted treatment strategy feasible for patients with MCL?
Is a response-adapted treatment strategy feasible for patients with MCL?
Jerkeman discusses the results from the MCL7 (VALERIA) trial, evaluating the feasibility of stopping treatment in molecular remission in patients with relapsed or refractory MCL treated with venetoclax, lenalidomide, and rituximab.
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox